查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917832

总体基因体学市场－2026-2031年预测

Metagenomics Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 146 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计总体基因体学市场将从 2025 年的 29.16 亿美元成长到 2031 年的 48.6 亿美元，复合年增长率为 8.89%。

元基因组总体基因体学涵盖了分析直接从环境和临床样本中提取的集体遗传物质（DNA/RNA）所需的各种技术、服务和生物资讯工具。这种方法无需分离和培养单一微生物，即可提供整个微生物群落组成、功能和动态的客观见解。该市场的发展主要得益于次世代定序（NGS）平台、专用样品製备盒、用于数据分析的先进计算软体以及相关的实验室服务。这代表着微生物学领域的模式转移，使得在实验室研究绝大多数无法培养的微生物成为可能，释放了以往难以触及的生物多样性和功能潜力。

市场扩张的根本驱动力在于高价值研究和商业领域的变革性应用。总体基因体学在药物发现和开发中日益重要的角色是关键的成长要素。筛检环境和宿主相关的微生物组，研究人员能够识别具有治疗潜力的新型生物合成基因丛集、酵素和生物活性化合物，在抗菌素抗药性日益严重的时代，为研发新型抗生素、抗癌药物和其他药物提供强有力的途径。同时，总体基因体学正在革新临床诊断。诸如鸟枪法元基因组组定序等技术能够实现无需预设假设的病原体检测、集体爆发监测以及复杂微生物组-疾病关联的阐明，其应用范围已从单一病原体检测扩展到全面的感染疾病和菌群失调分析。

另一个重要的驱动因素是核心平台技术的持续进步。新一代定序（NGS）技术的创新，例如更长的读长、更高的通量和更低的碱基成本，使得大规模元基因组调查变得更加容易。同样重要的是生物资讯学的进步，包括更强大的序列组装、分类和功能註释演算法，这些对于将原始数据转化为生物学见解至关重要。尤其重要的是长读长定序技术的整合，它能够从复杂的混合物中重建完整的微生物基因组，并提高分析精度。

从地理来看，亚太地区正崛起为重要的高成长市场，这大规模得益于政府和私部门对生命科学研究，特别是药物研发和精准医疗倡议的大量投资。各国为提升国内生物技术能力而製定的策略，正在催生对先进基因组学工具和服务的高度需求，使亚太地区成为市场扩张和战略投资的关键区域。

然而，儘管宏基因组学潜力巨大，但其市场推广仍面临许多障碍，主要与成本和复杂性相关。总体基因体学的总成本仍然很高，包括用于高通量定序的大量计算资源、专门的样本製备以及数据存储和分析。这种成本结构对于资金雄厚的研究中心以外的小规模学术实验室、医院和企业来说可能构成障碍。此外，该领域需要分子生物学、微生物学、生物资讯学和统计学等多种专业知识的综合运用。缺乏能够进行稳健的研究设计、处理复杂资料集以及在生物学背景下解读结果的熟练人员是阻碍因素。

竞争格局的特点是：大规模成熟的生命科学工具和诊断公司提供整合平台（定序仪、耗材和软体），而专业的生物资讯公司和服务供应商提供端到端的分析流程。竞争的焦点在于分类和功能分析的准确性和深度、分析软体的易用性和计算效率，以及提供能够降低终端用户技术门槛的承包解决方案的能力。成功的关键不仅在于处理大量资料集，还在于建立扩充性、可重复且可解释的工作流程，从而提供可操作的生物学见解。

总之，总体基因体学市场正引领我们理解和利用微生物世界能力的根本性扩展。其成长的结构性基础在于治疗方法发现和先进诊断等关键应用，并由持续的技术进步所驱动。对业内人士而言，策略重点应放在普及应用上，透过更自动化、基于云端的解决方案降低成本并简化生物资讯学的复杂性。未来的创新将聚焦于即时、可携式定序应用、多体学资料（宏转录组学、代谢体学）的整合，以及开发标准化资料库和分析框架，以提高研究间的可比较性。在这个市场取得成功不仅需要提供强大的工具，还需要建立必要的整合生态系统，将复杂的遗传数据转化为检验的科学发现以及切实可行的临床和产业成果。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

第五章总体基因体学市场（按类型划分）

  • 介绍
  • 标靶定序
  • 霰弹枪定序

第六章 依应用分類的总体基因体学学市场

  • 介绍
  • 疾病诊断
  • 疫苗研发
  • 药物发现
  • 其他的

第七章 依最终使用者分類的总体基因体学市场

  • 介绍
  • 製药和生物技术公司
  • 学术和研究机构
  • 其他的

第八章 各地区的总体基因体学市场

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章：竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十章：公司简介

  • Bio-Rad Laboratories Inc.
  • Illumina, Inc.
  • Thermo Fisher Scientific, Inc.
  • Novogene Co., Ltd.
  • QIAGEN
  • Takara Bio, Inc.
  • Oxford Nanopore Technologies plc
  • F. Hoffmann-La Roche Ltd.
  • Eurofins Scientific SE
  • BGI Group

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061616411

The metagenomics market is anticipated to increase at a 8.89% CAGR, from USD 2.916 billion in 2025 to USD 4.86 billion in 2031.

The metagenomics market encompasses the technologies, services, and bioinformatics tools required to analyze the collective genetic material (DNA/RNA) recovered directly from environmental or clinical samples, bypassing the need for isolating and culturing individual organisms. This approach provides an unbiased view of the composition, function, and dynamics of entire microbial communities. The market is propelled by next-generation sequencing (NGS) platforms, specialized library preparation kits, sophisticated computational software for data analysis, and associated laboratory services. It represents a paradigm shift in microbiology, enabling the study of the vast majority of microbes that are unculturable in the lab, thereby unlocking previously inaccessible biological diversity and functional potential.

Market expansion is fundamentally driven by its transformative applications across high-value research and commercial sectors. A primary growth catalyst is the burgeoning role of metagenomics in drug discovery and development. By screening environmental and host-associated microbiomes, researchers can identify novel biosynthetic gene clusters, enzymes, and bioactive compounds with therapeutic potential, offering a powerful route to new antibiotics, anticancer agents, and other pharmaceuticals in an era of rising antimicrobial resistance. Concurrently, metagenomics is revolutionizing clinical diagnostics. Techniques like shotgun metagenomic sequencing enable hypothesis-free pathogen detection, outbreak surveillance, and the characterization of complex microbiome-disease associations, moving beyond single-pathogen tests to comprehensive infectious disease and dysbiosis profiling.

A parallel and powerful driver is the continuous advancement of core enabling technologies. Innovations in NGS, such as increased read lengths, higher throughput, and reduced costs per base, are making large-scale metagenomic surveys more accessible. Equally critical are developments in bioinformatics, including more powerful algorithms for sequence assembly, taxonomic classification, and functional annotation, which are essential for transforming raw sequence data into biological insights. The integration of long-read sequencing technologies is particularly significant, improving the reconstruction of complete microbial genomes from complex mixtures and enhancing the accuracy of analyses.

Geographically, the Asia-Pacific region is emerging as a significant and high-growth market, propelled by substantial governmental and private investments in life sciences research, particularly in drug discovery and precision medicine initiatives. National strategies to build domestic biotechnology capacity are creating a concentrated demand for advanced genomic tools and services, positioning APAC as a key region for market expansion and strategic investment.

Despite its immense potential, the market faces substantial adoption barriers, primarily related to cost and complexity. The total expense of a metagenomics study remains significant, encompassing high-throughput sequencing runs, specialized sample preparation, and substantial computational resources for data storage and analysis. This cost profile can be prohibitive for smaller academic labs, hospitals, or industries outside of well-funded centers. Furthermore, the field requires a rare combination of expertise in molecular biology, microbiology, bioinformatics, and statistics. The scarcity of skilled personnel capable of designing robust studies, processing complex datasets, and interpreting results within a biological context is a major constraint on broader implementation.

The competitive landscape is characterized by large, established life science tools and diagnostics companies that provide integrated platforms (sequencers, consumables, software), alongside specialized bioinformatics firms and service providers offering end-to-end analytical pipelines. Competition centers on the accuracy and depth of taxonomic and functional profiling, the user-friendliness and computational efficiency of analysis software, and the ability to deliver turnkey solutions that lower the technical barrier for end-users. Success hinges on creating scalable, reproducible, and interpretable workflows that deliver actionable biological insights, not just vast datasets.

In conclusion, the metagenomics market is at the forefront of a fundamental expansion in our ability to understand and harness the microbial world. Its growth is structurally supported by critical applications in therapeutic discovery and advanced diagnostics, powered by relentless technological progress. For industry experts, strategic focus must center on democratizing access by driving down costs and simplifying bioinformatic complexity through more automated, cloud-based solutions. Future innovation will likely focus on real-time, portable sequencing applications, the integration of multi-omics data (metatranscriptomics, metabolomics), and the development of standardized databases and analytical frameworks to improve comparability across studies. Success in this market requires providing not just powerful tools, but the integrated ecosystem necessary to translate complex genetic data into validated scientific discoveries and tangible clinical or industrial outcomes.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Metagenomics Market Segmentation

  • By Type
  • Targeted Sequencing
  • Shot-Gun Sequencing
  • By Application
  • Disease Diagnostics
  • Vaccine Development
  • Drug Discovery
  • Others
  • By End-User
  • Pharmaceutical & Biotech Companies
  • Academic & Research Institutes
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. METAGENOMICS MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Targeted Sequencing
  • 5.3. Shot-Gun Sequencing

6. METAGENOMICS MARKET BY APPLICATION

  • 6.1. Introduction
  • 6.2. Disease Diagnostics
  • 6.3. Vaccine Development
  • 6.4. Drug Discovery
  • 6.5. Others

7. METAGENOMICS MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceutical & Biotech Companies
  • 7.3. Academic & Research Institutes
  • 7.4. Others

8. METAGENOMICS MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Bio-Rad Laboratories Inc.
  • 10.2. Illumina, Inc.
  • 10.3. Thermo Fisher Scientific, Inc.
  • 10.4. Novogene Co., Ltd.
  • 10.5. QIAGEN
  • 10.6. Takara Bio, Inc.
  • 10.7. Oxford Nanopore Technologies plc
  • 10.8. F. Hoffmann-La Roche Ltd.
  • 10.9. Eurofins Scientific SE
  • 10.10. BGI Group

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations